|
FY2025
12 months to Dec 31, 2025
|
|
|---|---|
| Cash flows from operating activities | |
| Net loss | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |
| Depreciation | |
| Stock-based compensation expense | |
| Net amortization of premiums and accretion of discounts on investments | |
| Common stock issued to NeuroSolis, Inc. | |
| Non-cash lease expense | |
| Loss on disposal of property and equipment | |
| Changes in operating assets and liabilities: | |
| Prepaid expenses and other assets | |
| Accounts payable | |
| Accrued expenses | |
| Operating lease liabilities | |
| Deferred grant earnings | |
| Net cash used in operating activities | |
| Cash flows from investing activities | |
| Purchases of short-term and long-term investments | |
| Maturities of marketable debt securities | |
| Purchases of property and equipment | |
| Net cash used in investing activities | |
| Cash flows from financing activities | |
| Payments of deferred financing costs | |
| Proceeds from issuance of Series D redeemable convertible preferred stock, net of issuance costs | |
| Proceeds from initial public offering of common stock and private placement, net of underwriting fees | |
| Proceeds from exercises of stock options | |
| Net cash provided by financing activities | |
| Increase (decrease) in cash, cash equivalents, and restricted cash | |
| Cash, cash equivalents, and restricted cash at beginning of period | |
| Cash, cash equivalents, and restricted cash at end of period | |
| Supplemental disclosure of non-cash investing and financing activities: | |
| Conversion of redeemable convertible preferred stock into common stock on closing of initial public offering |
Loading...
